Nicergoline

	WikiDoc Resources for Nicergoline
Articles
Most recent articles on Nicergoline Most cited articles on Nicergoline Review articles on Nicergoline Articles on Nicergoline in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Nicergoline Images of Nicergoline Photos of Nicergoline Podcasts & MP3s on Nicergoline Videos on Nicergoline
Evidence Based Medicine
Cochrane Collaboration on Nicergoline Bandolier on Nicergoline TRIP on Nicergoline
Clinical Trials
Ongoing Trials on Nicergoline at Clinical Trials.gov Trial results on Nicergoline Clinical Trials on Nicergoline at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Nicergoline NICE Guidance on Nicergoline NHS PRODIGY Guidance FDA on Nicergoline CDC on Nicergoline
Books
Books on Nicergoline
News
Nicergoline in the news Be alerted to news on Nicergoline News trends on Nicergoline
Commentary
Blogs on Nicergoline
Definitions
Definitions of Nicergoline
Patient Resources / Community
Patient resources on Nicergoline Discussion groups on Nicergoline Patient Handouts on Nicergoline Directions to Hospitals Treating Nicergoline Risk calculators and risk factors for Nicergoline
Healthcare Provider Resources
Symptoms of Nicergoline Causes & Risk Factors for Nicergoline Diagnostic studies for Nicergoline Treatment of Nicergoline
Continuing Medical Education (CME)
CME Programs on Nicergoline
International
Nicergoline en Espanol Nicergoline en Francais
Business
Nicergoline in the Marketplace Patents on Nicergoline
Experimental / Informatics
List of terms related to Nicergoline

Nicergoline
Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy; category	Not recommended;
Routes of; administration	Oral, IM, IV
ATC code	C04AE02 (WHO) ;
Legal status
Legal status	In general: Over-the-counter (OTC);
Pharmacokinetic data
Bioavailability	<5%
Protein binding	>90%
Metabolism	Extensive first-pass metabolism
Elimination half-life	13–20 hours
Identifiers
	IUPAC name [(8β)-10-methoxy-1,6-dimethylergolin-8-yl]methyl 5-bromopyridine-3-carboxylate;
CAS Number	27848-84-6 ;
PubChem CID	34040;
DrugBank	DB00699 ;
ChemSpider	31373 ;
UNII	JCV8365FWN;
KEGG	D01290 ;
ChEMBL	ChEMBL1372950;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C24H26BrN3O3
Molar mass	484.386 g/mol
3D model (JSmol)	Interactive image;
	SMILES Brc1cc(cnc1)C(=O)OC[C@@H]3C[C@]4(OC)c5cccc2c5c(cn2C)C[C@H]4N(C3)C;
	InChI InChI=1S/C24H26BrN3O3/c1-27-13-17-8-21-24(30-3,19-5-4-6-20(27)22(17)19)9-15(12-28(21)2)14-31-23(29)16-7-18(25)11-26-10-16/h4-7,10-11,13,15,21H,8-9,12,14H2,1-3H3/t15-,21-,24+/m1/s1 ; Key:YSEXMKHXIOCEJA-FVFQAYNVSA-N ;
(verify)

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Nicergoline (INN, marketed under the trade name Sermion) is an ergot derivative used to treat senile dementia and other disorders with vascular origins. It has been found to increase mental agility and enhance clarity and perception. It decreases vascular resistance and increases arterial blood flow in the brain, improving the utilization of oxygen and glucose by brain cells. It has similar vasoactive properties in other areas of the body, particularly the lungs.

It is used for vascular disorders such as cerebral thrombosis and atherosclerosis, arterial blockages in the limbs, Raynaud's disease, vascular migraines, and retinopathy.

Nicergoline has been registered in over fifty countries and has been used for more than three decades for the treatment of cognitive, affective, and behavioral disorders of older people.^[1]

Clinical Uses

Nicerogline is used in the following cases:

Acute and chronic cerebral metabolic-vascular disorders (cerebral arteriosclerosis, thrombosis and cerebral embolism, transitory cerebral ischaemia). Acute and chronic peripheral metabolic-vascular disorders (organic and functional arteriopathies of the limbs), Raynaud’s disease and other syndromes caused by altered peripheral irrigation.
Migraines of vascular origin
Coadjutant therapy in clinical situations accompanied by platelet hyper-aggregability, arterial tension.
Corio-retinal vascular disorders: diabetic retinopathy, macular degeneration and retinal angiosclerosis
Oto-vestibular problems of a vascular nature: dizziness, auditory hallucinations, hypoacusis.

Dosages for known conditions are usually administered at 5–10 mg three times a day, however anti-aging preventative purposes may want to consider 5 mg once or twice a day more adequate.^[2]

Contraindications

Persons suffering from acute bleeding, myocardial infarction (heart conditions), hypertension, bradycardia or using alpha or beta receptor agonists should consult with their physician before use. Although toxicology studies have not shown nicergoline to have any teratogenic effect, the use of this medicine during pregnancy should be limited to those cases where it is absolutely necessary.

On 28 June 2013 the European Medicines Agency recommended restricting the use of medicines containing ergot derivatives, including Nicergoline. They stated that "these medicines should no longer be used to treat several conditions involving blood circulation problems or problems with memory and sensation, or to prevent migraine headaches, since the risks are greater than the benefits in these indications. This is based on a review of data showing an increased risk of fibrosis (formation of excess connective tissue that can damage organs and body structures) and ergotism (symptoms of ergot poisoning, such as spasms and obstructed blood circulation) with these medicines." (http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001832.jsp&mid=WC0b01ac058004d5c1b)

Nicergoline is considered unsafe in porphyria.^[3]

Adverse Effects

The side effects of nicergoline are usually limited to nausea, hot flushes, mild gastric upset, hypotension and dizziness.^[3] At high dosages bradycardia, increased appetite, agitation, diarrhea and perspiration have been known to occur. A single case of acute interstitial nephritis has been reported.^[4]

Interactions

Nicergoline is known to enhance the cardiac depressive effects of propranolol.^[3] At high dosages, it is advisable to seek one’s physician's guidance if combining with potent vasodilators such as bromocriptine, Gingko biloba, picamilon, vinpocetine or xantinol nicotinate.

Mechanism of Action

Nicergoline is an ergot alkaloid derivative that acts as a potent and selective alpha-1A adrenergic receptor antagonist.^[5] The IC₅₀ of nicergoline in vitro has been reported to be 0.2 nM.^[6] The primary action of nicergoline is to increase arterial blood flow by vasodilation. Furthermore, it is known that nicergoline inhibits platelet aggregation. Studies have shown that nicergoline also increases nerve growth factor in the aged brain.

References

↑ Fioravanti M, Flicker L (2001). "Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment". Cochrane Database Syst Rev (4): CD003159. doi:10.1002/14651858.CD003159. PMID 11687175.
↑ Nicergoline drug insert, Pharmacia & Upjohn, October 2000
↑ ^3.0 ^3.1 ^3.2 Sweetman SC, ed. (2009). "Supplementary drugs and other substances". Martindale: The complete drug reference (36th ed.). London: Pharmaceutical Press. p. 2352. ISBN 978-0-85369-840-1.
↑ Kim MJ, Chang JH, Lee SK; et al. (2002). "Acute interstitial nephritis due to nicergoline (Sermion)". Nephron. 92 (3): 676–9. doi:10.1159/000064096. PMID 12372954.
↑ Alvarez-Guerra M, Bertholom N, Garay RP (1999). "Selective blockade by nicergoline of vascular responses elicited by stimulation of alpha 1A-adrenoceptor subtype in the rat". Fundam Clin Pharmacol. 13 (1): 50–8. PMID 10027088.
↑ Moretti A, Carfagna N, Caccia C, Carpentieri M (1988). "Effect of ergolines on neurotransmitter systems in the rat brain". Arch Int Pharmacodyn Ther. 294: 33–45. PMID 2906797.

External links

National Electronic Library for Medicines Nicergoline for dementia and other age associated forms of cognitive impairment.

Template:Peripheral vasodilators

[1] Fioravanti M, Flicker L (2001). "Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment". Cochrane Database Syst Rev (4): CD003159. doi:10.1002/14651858.CD003159. PMID 11687175.

[2] Nicergoline drug insert, Pharmacia & Upjohn, October 2000

[Martindale-3] 3.0 ^3.1 ^3.2 Sweetman SC, ed. (2009). "Supplementary drugs and other substances". Martindale: The complete drug reference (36th ed.). London: Pharmaceutical Press. p. 2352. ISBN 978-0-85369-840-1.

[4] Kim MJ, Chang JH, Lee SK; et al. (2002). "Acute interstitial nephritis due to nicergoline (Sermion)". Nephron. 92 (3): 676–9. doi:10.1159/000064096. PMID 12372954.

[5] Alvarez-Guerra M, Bertholom N, Garay RP (1999). "Selective blockade by nicergoline of vascular responses elicited by stimulation of alpha 1A-adrenoceptor subtype in the rat". Fundam Clin Pharmacol. 13 (1): 50–8. PMID 10027088.

[6] Moretti A, Carfagna N, Caccia C, Carpentieri M (1988). "Effect of ergolines on neurotransmitter systems in the rat brain". Arch Int Pharmacodyn Ther. 294: 33–45. PMID 2906797.

[1]

[2]

[3]

[4]

[5]

[6]

Clinical data

AHFS/Drugs.com	International Drug Names
Pregnancy category	Not recommended
Routes of administration	Oral, IM, IV
ATC code	C04AE02 (WHO)
Legal status
Legal status	In general: Over-the-counter (OTC)
Pharmacokinetic data
Bioavailability	<5%
Protein binding	>90%
Metabolism	Extensive first-pass metabolism
Elimination half-life	13–20 hours
Identifiers
IUPAC name [(8β)-10-methoxy-1,6-dimethylergolin-8-yl]methyl 5-bromopyridine-3-carboxylate
CAS Number	27848-84-6^Y
PubChem CID	34040
DrugBank	DB00699^Y
ChemSpider	31373^Y
UNII	JCV8365FWN
KEGG	D01290^Y
ChEMBL	ChEMBL1372950
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₄H₂₆BrN₃O₃
Molar mass	484.386 g/mol
3D model (JSmol)	Interactive image
SMILES Brc1cc(cnc1)C(=O)OC[C@@H]3C[C@]4(OC)c5cccc2c5c(cn2C)C[C@H]4N(C3)C
InChI InChI=1S/C24H26BrN3O3/c1-27-13-17-8-21-24(30-3,19-5-4-6-20(27)22(17)19)9-15(12-28(21)2)14-31-23(29)16-7-18(25)11-26-10-16/h4-7,10-11,13,15,21H,8-9,12,14H2,1-3H3/t15-,21-,24+/m1/s1^Y Key:YSEXMKHXIOCEJA-FVFQAYNVSA-N^Y
(verify)